HOME > TOP STORIES
TOP STORIES
-
REGULATORY Nitrosamine Self-Inspection Deadline Extended to Aug. 1 amid Challenges
August 1, 2024
-
BUSINESS Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
-
REGULATORY Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
-
BUSINESS Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
-
BUSINESS Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
-
BUSINESS EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
-
BUSINESS Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
-
BUSINESS Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
-
ORGANIZATION Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
July 25, 2024
-
BUSINESS Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
-
REGULATORY LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
-
BUSINESS Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
-
BUSINESS Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
-
REGULATORY Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
-
REGULATORY MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
-
REGULATORY Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
-
BUSINESS Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
-
BUSINESS LTL, Cheplapharm Envision Heightened Opportunities for LLP Takeovers under Elective Care Scheme
July 16, 2024
-
BUSINESS Meiji Paints Consortium Plan of Its Own, Woos Generic Peers to Join Scheme
July 16, 2024
-
BUSINESS Chiesi Joins Japan Rare Disease Market, Shoots for 10 Billion Yen Sales by 2030
July 12, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
